NCT00064090View on ClinicalTrials.gov

3-AP and Cytarabine in Treating Patients With Hematologic Cancer

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

March 31, 2003

Primary Completion Date

September 30, 2004

Study Completion Date

January 31, 2008

Conditions
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Interventions
DRUG

cytarabine

DRUG

triapine

Trial Locations (1)

77030-4095

University of Texas - MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Vion Pharmaceuticals

INDUSTRY

NCT00064090 - 3-AP and Cytarabine in Treating Patients With Hematologic Cancer | Biotech Hunter | Biotech Hunter